Potential additive or potentiating effect with CNS depressants. Specific interaction studies not conducted.
Source: NLP:brinzolamide/brimonidine tartrate
Brinzolamide/Brimonidine Tartrate Interactions
Brand names: Simbrinza
Carbonic Anhydrase Inhibitor · Carbonic Anhydrase Inhibitors
Route: Ophthalmic
Contraindications
4 CONTRAINDICATIONS Hypersensitivity to any component of this product. (4.1) Neonates and infants (under the age of two years). (4.2) 4.1 Hypersensitivity SIMBRINZA is contraindicated in patients who are hypersensitive to any component of this product. 4.2 Neonates and Infants (under the age of two years) SIMBRINZA is contraindicated in neonates and infants (under the age of two years ) [see Use in Specific Populations (8.4) ].
Pregnancy & Breastfeeding
8.1 Pregnancy Developmental toxicity studies with brinzolamide in rabbits at oral doses of 1, 3, and 6 mg/kg/day (20, 60, and 120 times the recommended human ophthalmic dose) produced maternal toxicity at 6 mg/kg/day and a significant increase in the number of fetal variations, such as accessory skull bones, which was only slightly higher than the historic value at 1 and 6 mg/kg. In rats, statistically decreased body weights of fetuses from dams receiving oral doses of 18 mg/kg/day (180 times the recommended human ophthalmic dose) during gestation were proportional to the reduced maternal weight gain, with no statistically significant effects on organ or tissue development. Increases in unossified sternebrae, reduced ossification of the skull, and unossified hyoid that occurred at 6 and 18 mg/kg were not statistically significant. No treatment-related malformations were seen. Following oral administration of 14 C-brinzolamide to pregnant rats, radioactivity was found to cross the placenta and was present in the fetal tissues and blood. Developmental toxicity studies performed in rats with oral doses of 0.66 mg brimonidine base/kg revealed no evidence of harm to the fetus. Dosing at this level resulted in a plasma drug concentration approximately 100 times higher than that seen in humans at the recommended human ophthalmic dose. In animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent. There are no adequate and well-controlled studies in pregnant women. SIMBRINZA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
9 interactions on record
May produce acid-base and electrolyte alterations. Rare instances reported with oral carbonic anhydrase inhibitors combined with high-dose salicylate therapy.
Source: NLP:brinzolamide/brimonidine tartrate
Potential additive or potentiating effect with CNS depressants. Specific interaction studies not conducted.
Source: NLP:brinzolamide/brimonidine tartrate
Brimonidine may reduce blood pressure; caution advised when used with cardiac glycosides.
Source: NLP:brinzolamide/brimonidine tartrate
Potential for additive effect on systemic effects of carbonic anhydrase inhibition. Concomitant administration not recommended.
Source: NLP:brinzolamide/brimonidine tartrate
May theoretically interfere with brimonidine metabolism and potentially increase systemic side effects such as hypotension.
Source: NLP:brinzolamide/brimonidine tartrate
Potential additive or potentiating effect with CNS depressants. Specific interaction studies not conducted.
Source: NLP:brinzolamide/brimonidine tartrate
Potential additive or potentiating effect with CNS depressants. Specific interaction studies not conducted.
Source: NLP:brinzolamide/brimonidine tartrate
7 DRUG INTERACTIONS Oral Carbonic Anhydrase Inhibitors (7.1) High-dose Salicylate Therapy (7.2) Central Nervous System Depressants (7.3) Antihypertensives/Cardiac Glycosides (7.4) Tricyclic Antidepressants (7.5) Monoamine Oxidase (MAO) Inhibitors (7.6) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and brinzolamide ophthalmic suspension 1%, a component of SIMBRINZA ophthalmic suspension. These alterations were not reported in the clinical trials with brinzolamide ophthalmic suspension 1%.
Source: FDA drug label - brinzolamide/brimonidine tartrate